These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23235317)

  • 21. Affinity enhancement of HER2-binding Z(HER2:342) affibody via rational design approach: a molecular dynamics study.
    Ghaffari MA; Zeinali M; Barzegari Asadabadi E; Jamalan M; Jahandideh S
    J Biomol Struct Dyn; 2014 Dec; 32(12):1919-28. PubMed ID: 24125055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
    Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J
    J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection and characterization of HER2/neu-binding affibody ligands.
    Wikman M; Steffen AC; Gunneriusson E; Tolmachev V; Adams GP; Carlsson J; Ståhl S
    Protein Eng Des Sel; 2004 May; 17(5):455-62. PubMed ID: 15208403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific interactions between human integrin alpha v beta 3 and chimeric hepatitis B virus core particles bearing the receptor-binding epitope of foot-and-mouth disease virus.
    Sharma A; Rao Z; Fry E; Booth T; Jones EY; Rowlands DJ; Simmons DL; Stuart DI
    Virology; 1997 Dec; 239(1):150-7. PubMed ID: 9426454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate.
    Govindarajan S; Sivakumar J; Garimidi P; Rangaraj N; Kumar JM; Rao NM; Gopal V
    Biomaterials; 2012 Mar; 33(8):2570-82. PubMed ID: 22192536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
    Barrajón-Catalán E; Menéndez-Gutiérrez MP; Falco A; Carrato A; Saceda M; Micol V
    Cancer Lett; 2010 Apr; 290(2):192-203. PubMed ID: 19896266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.
    Lu Y; Chan W; Ko BY; VanLang CC; Swartz JR
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12360-5. PubMed ID: 26392546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleic acid chaperone activity associated with the arginine-rich domain of human hepatitis B virus core protein.
    Chu TH; Liou AT; Su PY; Wu HN; Shih C
    J Virol; 2014 Mar; 88(5):2530-43. PubMed ID: 24352445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery
    Suffian IFM; Wang JT; Faruqu FN; Benitez J; Nishimura Y; Ogino C; Kondo A; Al-Jamal KT
    ACS Appl Nano Mater; 2018 Jul; 1(7):3269-3282. PubMed ID: 30613831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.
    Ghanemi M; Pourshohod A; Ghaffari MA; Kheirollah A; Amin M; Zeinali M; Jamalan M
    Curr Cancer Drug Targets; 2019; 19(1):65-73. PubMed ID: 28460618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.
    Zhang Y; Jiang S; Zhang D; Bai X; Hecht SM; Chen S
    Chem Commun (Camb); 2017 Jan; 53(3):573-576. PubMed ID: 27975087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mosaic particles formed by wild-type hepatitis B virus core protein and its deletion variants consist of both homo- and heterodimers.
    Kazaks A; Dishlers A; Pumpens P; Ulrich R; Krüger DH; Meisel H
    FEBS Lett; 2003 Aug; 549(1-3):157-62. PubMed ID: 12914943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein.
    Yang X; Xia X; Xia XX; Sun Z; Yan D
    Mol Pharm; 2021 Oct; 18(10):3854-3861. PubMed ID: 34543035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of three different recombinant hepatitis B virus core particles expressed in Escherichia coli.
    Maassen A; Rehfeldt A; Kiessig S; Ladhoff A; Höhne WE; Meisel H
    Arch Virol; 1994; 135(1-2):131-42. PubMed ID: 8198438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis for high-affinity HER2 receptor binding by an engineered protein.
    Eigenbrot C; Ultsch M; Dubnovitsky A; Abrahmsén L; Härd T
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15039-44. PubMed ID: 20696930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescent protein tagged hepatitis B virus capsid protein with long glycine-serine linker that supports nucleocapsid formation.
    Chen JY; Gan CY; Cai XF; Zhang WL; Long QX; Wei XF; Hu Y; Tang N; Chen J; Guo H; Huang AL; Hu JL
    J Virol Methods; 2018 May; 255():52-59. PubMed ID: 29447911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z
    Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
    Mol Biol Rep; 2020 Sep; 47(9):7139-7151. PubMed ID: 32929653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins.
    Pioquinto-Avila E; González-Cruz AO; Solís-Estrada J; Hernández-Juarez J; Balderas-Rentería I; Villa-Cedillo SA; Pérez-Trujillo JJ; Arredondo-Espinoza E
    Anticancer Res; 2024 Jun; 44(6):2567-2575. PubMed ID: 38821612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yield Optimisation of Hepatitis B Virus Core Particles in E. coli Expression System for Drug Delivery Applications.
    Bin Mohamed Suffian IF; Garcia-Maya M; Brown P; Bui T; Nishimura Y; Palermo AR; Ogino C; Kondo A; Al-Jamal KT
    Sci Rep; 2017 Mar; 7():43160. PubMed ID: 28256592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.